Clinical Trials

1 trials
RecentStart dateEnrollment
Mast Cell Activation Disorders × ripretinib × Lymphoid × Clear all
NCT02571036 2023-12-13

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

Deciphera Pharmaceuticals, LLC

Phase 1 Completed
282 enrolled
CNSDermatologicGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmSarcomaThoracic

Mast Cell Activation Disorders, Carcinoma, Non-Small-Cell Lung, Glioma, Leukemia, Mast-Cell, Melanoma, Neoplasms, Germ Cell and Embryonal, Penile Neoplasms, Sarcoma, Mastocytosis, Systemic, Gastrointestinal Stromal Tumors, Renal Insufficiency